Scancell Holdings PLC · LSE:SCLP

Scancell — Shareholder Meeting (October 2015)

20 slides from Scancell's shareholder meeting presentation, Oct 20, 2015

  1. Slide 1: Innovation in Immuno-Oncology

    Slide 1: Innovation in Immuno-Oncology

    INNOVATION in IMMUNO-­‐ONCOLOGY AGM Presenta,on: October 20th 2015 Dr Richard Goodfellow: Co-­‐CEO, Scancell Holdings plc Prof Lindy Durrant: Co-­‐CEO, Scancell Holdings plc 1

  2. Slide 2: Company Profile

    Slide 2: Company Profile

    COMPANY PROFILE Translating innovative science into ground-­‐breaking new products Ø Focus on cancer immunotherapy Ø Two cu>ng edge pla?orm technologies – ImmunoBody® and Moditope® Ø Outstanding clinical efficacy and safety on lead product SCIB1 for paHents with stage III/IV resected metastaHc mela

  3. Slide 3: Value Drivers

    Slide 3: Value Drivers

    VALUE DRIVERS Ultra high T cell avidity delivers outstanding efIicacy and safety Ø SCIB1 combined with checkpoint inhibitors for late stage disease and as monotherapy in adjuvant melanoma Ø ExcepHonal survival and safety in resected stage III/IV paHents Ø Checkpoint inhibitors only have 25-­‐30%

  4. Slide 4: Future Plans

    Slide 4: Future Plans

    FUTURE PLANS A Road Map for the future Ø A phase 2 controlled randomised clinical trial to confirm efficacy of SCIB1 in combinaHon with checkpoint inhibitors Ø A phase 3 adjuvant melanoma study Ø Phase 1/2 clinical trial with Modi-­‐1 in breast and ovarian cancer Ø Strengthen Board and management c

  5. Slide 5: SCIB1-001 Study Design Used for Phase 1/2 Trial

    Slide 5: SCIB1-001 Study Design Used for Phase 1/2 Trial

    SCIB1-­‐001 STUDY DESIGN USED FOR PHASE 1/2 TRIAL PART 1 – Dose escalation in patients with stage III/IV melanoma (with or without tumour) Ø Primary ObjecHve – safety and tolerability Ø Secondary ObjecHves – immune responses; tumour responses Dose escalaHon with safety assessment a_er 3 doses (0.4

  6. Slide 6: SCIB1 Clinical Trial – Highlights

    Slide 6: SCIB1 Clinical Trial – Highlights

    SCIB1 CLINICAL TRIAL – HIGHLIGHTS Ø All 20 paHents with resected tumours at study entry remain alive Ø Two paHents with tumour present at study entry have shown a reducHon in tumour size or complete destrucHon of tumours Patient'04*16' Patient'04*28' !(i)!Pre(treatment !(ii)!9!months! !(i)!Pre(tre

  7. Slide 7: Survival of All Resected Patients

    Slide 7: Survival of All Resected Patients

    SURVIVAL OF ALL RESECTED PATIENTS Ø 16 paHents received 2-­‐4 mg doses of SCIB1 Ø All remain alive Ø 31% have progressed Ø Median observaHon Hme = 39 months from study entry Ø Compares favourably with other studies Ø Five conHnue to receive further doses of SCIB1 SCIB1%median%follow%up%at%%39%

  8. Slide 8: Summary of SCIB1

    Slide 8: Summary of SCIB1

    SUMMARY OF SCIB1 Ø Scancell’s ImmunoBody® pla?orm, in combinaHon with electroporaHon, sHmulates potent T cell responses Ø SCIB1 shrinks and even destroys tumours in paHents with inoperable metastaHc melanoma Ø SCIB1 prevents disease recurrence and prolongs overall survival in paHents with fully r

  9. Slide 9: Moditope

    Slide 9: Moditope

    MODITOPE® Ø Moditope® is a new and proprietary pla?orm for acHvaHng the immune system against tumour cells Ø Moditope® exploits the normal immune response to stressed cells, which is largely mediated by cytotoxic CD4+ T cells Ø When normal cells are stressed or dying, they start to digest their o

  10. Slide 10: Moditope Progress Update – Components of First Candidate Modi-1 Identified

    Slide 10: Moditope Progress Update – Components of First Candidate Modi-1 Identified

    MODITOPE® PROGRESS UPDATE – 1 Components of Iirst Moditope® development candidate, Modi-­‐1, identiIied Ø First target was vimenHn – a major cytoskeletal protein, with two citrullinated vimenHn pepHdes selected for inclusion in Modi-­‐1 Ø AddiHonal enolase pepHde idenHfied, inclusion of which signi

  11. Slide 11: Moditope Progress Update – Modi-1 Potentially Effective in Up to 95% of Population

    Slide 11: Moditope Progress Update – Modi-1 Potentially Effective in Up to 95% of Population

    MODITOPE® PROGRESS UPDATE – 2 Modi-­‐1 has the potential to be effective in up to 95% of the population Ø Previous studies indicated that only paHents with a parHcular haplotype, HLA-­‐DR4, would respond to vimenHn and enolase pepHdes (approximately 25% of populaHon) Ø Scancell has now shown that

  12. Slide 12: Moditope Progress Update – First Biologically Relevant Animal Model

    Slide 12: Moditope Progress Update – First Biologically Relevant Animal Model

    MODITOPE® PROGRESS UPDATE – 3 Scancell has developed the world’s Iirst biologically relevant animal model for the detection of CD4 T cell responses Ø Most tumours do not express MHC-­‐II unless it is induced by inflammaHon and are therefore not targets for CD4 T cells Ø Gamma interferon-­‐inducible

  13. Slide 13: Moditope Conclusions

    Slide 13: Moditope Conclusions

    MODITOPE® CONCLUSIONS Ø Moditope® pla?orm exemplified by lead product Mod-­‐1 Ø Modi-­‐1 pepHde components increased to extend tumour coverage and paHent eligibility Ø OpHmised Modi-­‐1 now suitable for treatment of up to 95% of paHents rather than 25% (due to HLA restricHon) Ø Inclusion of Eno-­

  14. Slide 14: Clinical Development Plans

    Slide 14: Clinical Development Plans

    CLINICAL DEVELOPMENT PLANS Ø SCIB1 + checkpoint inhibitor combinaHon phase 2 study Ø SCIB1 adjuvant phase 3 study Ø Modi-­‐1 phase 1/2 clinical study 14

  15. Slide 15: SCIB1 + Checkpoint Inhibitor Combination

    Slide 15: SCIB1 + Checkpoint Inhibitor Combination

    SCIB1 + CHECKPOINT INHIBITOR COMBINATION RATIONALE Ø Checkpoint inhibitors targeHng PD-­‐1 have yielded impressive results in the treatment of paHents with metastaHc melanoma Ø Despite this success, response rates have not exceeded 25-­‐30% Ø A majority of paHents may not respond to PD-­‐1 inhibi

  16. Slide 16: SCIB1 Synergy in Combination with Anti-PD.1

    Slide 16: SCIB1 Synergy in Combination with Anti-PD.1

    SCIB1 SYNERGY IN COMBINATION WITH ANTI-­‐PD.1 Ø Immunised with SCIB1, murine-­‐specific anH-­‐PD.1 anHbody or both SCIB1 + anH-­‐PD.1 Ø SCIB1 provides equivalent survival compared to inhibiHng PD.1 Ø Combining anH-­‐PD.1 therapy with SCIB1 significantly enhances survival, resulHng in 85% survival o

  17. Slide 17: Our Vision for Future Immunotherapy of Melanoma

    Slide 17: Our Vision for Future Immunotherapy of Melanoma

    OUR VISION FOR FUTURE IMMUNOTHERAPY OF MELANOMA Stage * Incidence 5 year Therapy (%) survival (%) 1A 97 Surgery 67 IB 92 Surgery IIA 81 Surgery, SCIB1 IIB 19 70 Surgery, SCIB1 IIC 53 Surgery, SCIB1 IIIA** 78 Surgery, SCIB1 IIIB 11 59 Surgery, SCIB1, checkpoint inhibitors, BRAF inhibitors IIIC 40 Sur

  18. Slide 18: SCIB1 Adjuvant Phase 3 Study

    Slide 18: SCIB1 Adjuvant Phase 3 Study

    SCIB1 ADJUVANT PHASE 3 STUDY TARGET INDICATION: Adjuvant therapy in melanoma patients with fully-­‐resected disease Ø Treatment of paHents a_er surgical removal of tumours Ø Therapy targeted at metastaHc disease which rapidly leads to disease recurrence Ra,onale Ø Currently over 360,000 paHents i

  19. Slide 19: Phase 1/2 Study of Modi-1 in Patients with Advanced Malignancy

    Slide 19: Phase 1/2 Study of Modi-1 in Patients with Advanced Malignancy

    PHASE 1/2 STUDY OF MODI-­‐1 IN PATIENTS WITH ADVANCED MALIGNANCY Ø A first-­‐in-­‐human phase 1/2 study of Modi-­‐1 in paHents with advanced malignancy for whom no standard therapy is considered appropriate, or for whom standard therapy is considered intolerable Ø Phase 1 will assess the safety and

  20. Slide 20: Potential Synergy Between ImmunoBody and Moditope

    Slide 20: Potential Synergy Between ImmunoBody and Moditope

    POTENTIAL SYNERGY BETWEEN IMMUNOBODY® AND MODITOPE® ImmunoBody® Moditope® High avidity CD8+ T cell responses Potent CD4+ T cell responses DNA product PepHde product Eradicates small primary and Eradicates large bulky tumours metastaHc tumours Checkpoint inhibitors may enhance No requirement for chec

Source: Internet Archive copy of scancell.co.uk

More decks from Scancell Holdings PLC

All 23 Scancell decks